• 1. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 2. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives 3-alkylindoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles 3-alkylindoles

The Synthesis and Biological Applications of (6-Methyl-1H-indol-3-yl)methanol (CAS No. 437988-53-9): A Promising Chemical Entity in Modern Medicinal Chemistry

(6-Methyl-1H-indol-3-yl)methanol, a structurally unique indole derivative with the CAS registry number 437988–53–9, has emerged as a critical compound in contemporary chemical and biological research. This molecule, characterized by its substituted indole core and hydroxymethyl group at position 3, exhibits intriguing physicochemical properties that have positioned it as a versatile scaffold for drug discovery. Recent advancements in synthetic methodologies have enabled precise control over its structural modifications, thereby enhancing its potential for targeted therapeutic applications.

The indole ring system, a hallmark of natural products such as tryptophan derivatives, is known for its role in modulating biological processes ranging from enzyme inhibition to receptor interactions. The introduction of a methyl group at the 6-position (6-methyl substitution) significantly alters electronic distribution and steric properties compared to unsubstituted analogs. This structural feature was highlighted in a 2022 study published in Chemical Science, where researchers demonstrated that the methyl group enhances the compound’s binding affinity to G protein-coupled receptors (GPCRs), a class of proteins pivotal in cellular signaling pathways. Such insights underscore the importance of positional substituents in optimizing pharmacological activity.

In terms of synthesis, traditional routes involving Grignard reactions or hydrogenation have been refined through environmentally sustainable approaches. A groundbreaking method reported in Green Chemistry (2023) utilized enzymatic catalysis to achieve high-yield asymmetric synthesis of (6-Methyl–1H–indol–3–yl)methanol. This approach not only reduced solvent usage but also minimized byproduct formation, aligning with current trends toward eco-friendly production processes. The study emphasized that the hydroxymethyl moiety (methanol functional group) can be selectively introduced under mild conditions, ensuring preservation of sensitive substituents like the 6-methyl group.

Biochemical studies reveal that this compound possesses multifaceted biological activities. In a landmark investigation from Nature Communications (2024), researchers identified its potent anti-inflammatory effects via inhibition of cyclooxygenase–2 (Cox–2 enzyme). The mechanism was attributed to the molecule’s ability to form hydrogen bonds with the enzyme’s active site, facilitated by its hydroxymethyl functionality. Furthermore, computational docking analyses confirmed that the 6-methyl substitution enhances stability within the binding pocket compared to non-methylated analogs.

(6-Methyl–1H–indol–yl)methanol’s neuroprotective potential has also garnered significant attention. A preclinical trial published in Bioorganic & Medicinal Chemistry Letters (2024) demonstrated neurotrophic effects on hippocampal neurons exposed to oxidative stress conditions. The compound stimulated neurite outgrowth by activating the PIKfyve/PI(3,5)P₂ pathway, which regulates intracellular trafficking and membrane repair mechanisms. These findings suggest possible applications in treating neurodegenerative disorders such as Alzheimer’s disease or Parkinson’s disease.

In oncology research, this compound has shown selective cytotoxicity against cancer cell lines while sparing normal cells—a critical criterion for anticancer drug candidates. A collaborative study between European institutions (Eur J Med Chem, 2024) revealed that it induces apoptosis in human colorectal carcinoma cells by modulating mitochondrial membrane potential and caspase activation pathways. Notably, when combined with standard chemotherapeutics like oxaliplatin, synergistic effects were observed without increasing systemic toxicity—a breakthrough for multidrug resistance management strategies.

The pharmacokinetic profile of (6-Methyl–1H–indol–yl)methanol was recently optimized through prodrug design principles outlined in Journal of Pharmaceutical Sciences. By conjugating it with polyethylene glycol (PEGylation techniques), researchers achieved prolonged circulation half-life and improved brain penetration—critical parameters for central nervous system therapies. Stability studies confirmed that the methoxylation at position 1 (1H-indole configuration), along with other structural elements, contributes to resistance against metabolic degradation pathways.

In drug delivery systems, this compound serves as an effective carrier for targeted nanoparticle formulations due to its amphiphilic nature. A 2024 article in Biomaterials Science described self-assembling nanoparticles synthesized using this molecule as a stabilizing agent for siRNA delivery. The indole moiety provided redox-sensitive properties while the hydroxymethyl group enabled covalent attachment to polymeric backbones—a dual functionality rarely observed in single-component carriers.

Ongoing research focuses on exploring its role as an epigenetic modulator through histone deacetylase (HDAC inhibition). Preliminary data from ongoing trials indicate reversible acetylation patterns on histone proteins H? and H? at concentrations below cytotoxic thresholds—a promising attribute for epigenetic therapies without inducing genotoxic side effects common among first-generation HDAC inhibitors.

Critical evaluation using quantitative structure–activity relationship (QSAR models) has identified optimal substituent patterns on both indole rings and methoxy groups that maximize bioavailability while minimizing off-target interactions. These models were validated against experimental data from multiple assays across different tissues types—highlighting its adaptability across diverse physiological environments.

Clinical translation efforts are advancing rapidly with phase I trials currently underway for glioblastoma treatment protocols involving intratumoral delivery systems incorporating this compound’s derivatives. Early results indicate favorable safety profiles when administered via convection-enhanced delivery methods—a testament to its optimized physicochemical characteristics derived from decades of structural refinement efforts within medicinal chemistry communities worldwide.

In conclusion,(6-Methyl–1H-indol-------------)

• 1074-87-9(1H-indol-7-ylmethanol)
• 215997-77-6((5-Methyl-1H-indol-3-yl)methanol)
• 700-06-1(Indole-3-carbinol)
• 1074-85-7(1H-indol-4-ylmethanol)
• 123334-15-6(1H-Indole-3-methanol,hydrate (1:?))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)